Disease landscape
Diabetes Mellitus
The substantial restrictions in diagnosis and access to diabetes mellitus have been identified in the Visegrád (V4) states as measured in the GAP score, with a clear difference between them. The difference between the highest and the lowest scoring country is 38 points. The main reasons for the downgrading are the limited access to registered drugs due to the lack of reimbursement or the high reimbursement restrictions, and the low proportion of patients treated with drugs authorised since 2010, especially in Poland.
Cross-Country
General GAP for Diabetes Mellitus
Compliance with guidelines
Positive recommendations for 27 diabetes mellitus drugs were found in the clinical practice guidelines and there is a huge inequality between the countries as the treatment compliance with guidelines is only 26% in Poland (severe limitations in access) and 60-80% in the remaining states (moderate to low limitations to access).
From registration to reimbursement
Population burden
DALY* - Rate per 100k
*disability adjusted life-years
Target population
Diabetes prevalence
Estimated diabetes prevalence (GBD).
Drug access
Number of patientS treated with drugs registered in 2011-2023
Drug access
Population treated* (%)
*percentage of patients treated with drugs registered in 2011-2023
Main issues
- The average time to reimbursement for diabetes drugs in the V4 countries is 2.1 years. The difference between the shortest and the longest mean time to reimbursement among the countries is 5.4 years.
- The uptake of drugs authorised since 2010 is low, below 21%.
- DALY (disability adjusted life years) burden in the V4 countries, apart from Slovakia, is clearly higher than the European Union average. An increasing trend of DALY burden was observed in 1995-2019 in V4 countries, which is in line with the observations for the EU.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).